[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Lee DW, Kim YT, Kim JH, Kim S, Kim SW, Nam EJ, Kim JW: Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy. J Gynecol Oncol; 2010 Mar;21(1):18-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy.
  • OBJECTIVE: The purpose of this study was to evaluate the prognostic significance of tumor volume assessed by pretreatment MRI in stage IIB cervical cancer patients with concurrent chemoradiation therapy.
  • METHODS: A retrospective chart review was performed on seventy five patients with cervical cancer who were treated with concurrent weekly cisplatin (40 mg/m(2)) and radiotherapy between January 2000 and April 2007.
  • Potential prognostic factors were age, chemotherapy numbers, histology, tumor diameter and volume, lymph node (LN) involvement and pretreatment squamous cell carcinoma antigen (SCC-Ag) levels.
  • RESULTS: The median follow-up time was 55 months (range, 8 to 104 months).
  • CONCLUSION: Tumor volume and pelvic LN involvement showed possibility to predict overall survival in patient with stage IIB cervical cancer.
  • Optimal tumor volume and pelvic LN assessment by pretreatment MRI might be helpful to predict treatment outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Magn Reson Q. 1994 Mar;10(1):22-42 [8161484.001]
  • [Cites] Cancer. 1990 May 1;65(9):1923-7 [2372764.001]
  • [Cites] AJR Am J Roentgenol. 1996 Nov;167(5):1101-8 [8911159.001]
  • [Cites] AJR Am J Roentgenol. 1998 Sep;171(3):707-11 [9725301.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1547-54 [10193945.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):41-5 [10458216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):639-44 [10524417.001]
  • [Cites] Zentralbl Gynakol. 2000;122(2):82-91 [10721187.001]
  • [Cites] Int J Gynecol Cancer. 2001 Jul-Aug;11(4):263-71 [11520363.001]
  • [Cites] Gynecol Oncol. 2002 Jan;84(1):115-9 [11748986.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):14-22 [11777618.001]
  • [Cites] Radiol Clin North Am. 2002 May;40(3):577-90, vii [12117194.001]
  • [Cites] Acta Obstet Gynecol Scand. 2002 Dec;81(12):1144-51 [12519111.001]
  • [Cites] Am J Clin Oncol. 2003 Oct;26(5):e163-8 [14528092.001]
  • [Cites] Tumour Biol. 2003 May-Jun;24(3):156-64 [14610320.001]
  • [Cites] J Comput Assist Tomogr. 2004 Sep-Oct;28(5):620-7 [15480035.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1663-6 [16033078.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7454-9 [16234512.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):995-1001 [16343175.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1094-100 [16803491.001]
  • [Cites] Cancer. 1992 Apr 1;69(7):1750-8 [1551060.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(3):491-9 [1612949.001]
  • [Cites] Cancer. 1992 Aug 1;70(3):648-55 [1623479.001]
  • [Cites] Gynecol Oncol. 1990 Nov;39(2):175-80 [2227592.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Apr 30;29(1):9-16 [8175451.001]
  • (PMID = 20379443.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2849943
  • [Keywords] NOTNLM ; Cervical neoplasms / Chemoradiation therapy / MRI / Tumor volume
  •  go-up   go-down


2. Lim MC, Kim JY, Kim TH, Park S, Kong SY, Yoon JH, Kang S, Seo SS, Park SY: Allogeneic blood transfusion given before radiotherapy is associated with the poor clinical outcome in patients with cervical cancer. Yonsei Med J; 2008 Dec 31;49(6):993-1003
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic blood transfusion given before radiotherapy is associated with the poor clinical outcome in patients with cervical cancer.
  • PURPOSE: To analyze the effect of allogeneic blood transfusion on clinical outcome in 119 patients with stage IIB cervical cancer who were treated with radiotherapy +/- chemotherapy.
  • PATIENTS AND METHODS: Medical records were examined for hemoglobin levels before and during radiotherapy, history of allogeneic blood transfusions and the time point when transfusions were given.
  • When patients who received transfusions were sub-divided by the time of transfusion, those who received transfusions before radiotherapy had significantly poorer clinical outcome than those who received transfusions during radiotherapy.
  • CONCLUSION: Our results suggest that allogeneic blood transfusions given before radiotherapy may be associated with higher incidence of distant metastases and decreased survival in patients with stage IIB cervical cancer.
  • [MeSH-major] Blood Transfusion / adverse effects. Uterine Cervical Neoplasms / radiotherapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia / etiology. Anemia / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Female. Humans. Middle Aged. Prognosis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Blood Transfusion and Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Biol. 1999 Oct;75(10):1293-7 [10549606.001]
  • [Cites] Oncology. 2005;69 Suppl 2:17-21 [16244506.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):24-31 [11328275.001]
  • [Cites] Int J Radiat Biol. 2001 Dec;77(12):1185-93 [11747543.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Apr;42(1):65-78 [11923069.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1345-55 [12459356.001]
  • [Cites] Strahlenther Onkol. 2002 Dec;178(12):727-31 [12491062.001]
  • [Cites] J Trauma. 2003 May;54(5):908-14 [12777903.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1514-20 [14508840.001]
  • [Cites] Mayo Clin Proc. 2003 Oct;78(10):1274-80 [14531486.001]
  • [Cites] Int J Gynecol Cancer. 2003 Sep-Oct;13(5):633-9 [14675347.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70 [14967443.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):67-71 [15093900.001]
  • [Cites] Circulation. 2004 Jun 8;109(22):2755-60 [15148271.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):903-10 [15361202.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):145-51 [15385124.001]
  • [Cites] Radiology. 1975 Nov;117(2):459-65 [1178882.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4677-81 [2547512.001]
  • [Cites] Int J Cancer. 1993 Dec 2;55(6):996-1002 [8253537.001]
  • [Cites] Surgery. 1994 Mar;115(3):303-9 [8128355.001]
  • [Cites] Am J Surg. 1994 Oct;168(4):340-4 [7943591.001]
  • [Cites] Arch Surg. 1996 Apr;131(4):438-41 [8615733.001]
  • [Cites] Anesthesiology. 1996 Nov;85(5):1219-20 [8916854.001]
  • [Cites] Vox Sang. 1998;74 Suppl 2:315-9 [9704462.001]
  • [Cites] Strahlenther Onkol. 2004 Nov;180(11):671-81 [15549184.001]
  • [Cites] Am J Obstet Gynecol. 2004 Dec;191(6):1907-13 [15592271.001]
  • [Cites] Cancer Radiother. 2005 Mar;9(2):87-95 [15820436.001]
  • [Cites] Cancer Treat Rev. 2005 May;31(3):159-72 [15923088.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):25-36 [16111569.001]
  • [Cites] Hematology. 2005;10 Suppl 1:208-14 [16188675.001]
  • [Cites] Radiother Oncol. 2000 Oct;57(1):13-9 [11033184.001]
  • (PMID = 19108024.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2628023
  •  go-up   go-down


3. Gupta G, Hafiz A, Gandhi JS: Radiation-induced chondrosarcomas: a case report with review of literature. J Cancer Res Ther; 2010 Jul-Sep;6(3):394-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiation therapy has become an important component of various cancer treatments.
  • The development of second malignancy as a result of radiation therapy is a well-known sinister complication.
  • However, radiation-induced sarcomas (RIS) are rare complications of radiation therapy.
  • Radiation-induced sarcomas per se are very rare and those with histomorphology of chondrosarcomas are even rarer.
  • We report a rare case of RIS of left iliac bone in a 62-year-old lady after combined chemotherapy and external beam radiation therapy for cervical carcinoma (stage IIb).
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Uterine Cervical Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119289.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  •  go-up   go-down


Advertisement
4. Kobierski J, Mielcarek P, Brzóska B, Królikowska B, Emerich J: [Neoadjuvant chemotherapy in the treatment of advanced cervical cancer]. Ginekol Pol; 2002 Sep;73(9):807-10
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant chemotherapy in the treatment of advanced cervical cancer].
  • Neoadjuvant chemotherapy (NAC) has been used for treatment of advanced cervical cancer by some institutions for several years.
  • PURPOSE: We investigated the value of NAC for patients with IIb cervical cancer.
  • MATERIALS AND METHODS: Eight patients treated at the 2nd Department of Obstetrics and Gynecology Medical University of Gdansk between 1999 and 2000 for stage IIb cervical cancer were enrolled into the study.
  • The drugs infused were: cisplatin 50 mg/m(2) and vincristine 1 mg/m(2) for 1 day and bleomycin 25 mg/m(2) for 3 days, for three cycles.
  • Hematological toxicity was mild and there was no need for modifying chemotherapy due to side effect of NAC.
  • CONCLUSION: NAC followed by radical Wertheim-Meigs hysterectomy is an effective approach to stage IIB cervical cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoadjuvant Therapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Poland. Time Factors. Treatment Outcome. Vincristine / administration & dosage


5. Corrado G, Santaguida S, Zannoni G, Scambia G, Ferrandina G: Femur metastasis in carcinoma of the uterine cervix: a rare entity. Arch Gynecol Obstet; 2010 May;281(5):963-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Femur metastasis in carcinoma of the uterine cervix: a rare entity.
  • PURPOSE: We report the first case of isolated femur metastasis in a locally advanced cervical cancer (LACC) patients.
  • CASE: A 40-year-old woman presenting with carcinoma of the uterine cervix, FIGO stage IIb was administered concomitant chemo-radiation and achieved clinical partial response.
  • Before the planned surgery, she developed an isolated metastatic lytic lesion of the left femur.
  • After surgical excision of metastasis, she refused palliative chemotherapy, and radiotherapy, and died 3 months later because of progression of the disease.
  • Because the prognosis of these patients is poor and most of them die within 1 year after the diagnosis of metastatic disease, the policy of treatment should be directed to maintain their quality of life.
  • [MeSH-major] Carcinoma / secondary. Femoral Neoplasms / secondary. Femur / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Curr Opin Oncol. 2009 Sep;21(5):420-4 [19553814.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1085-91 [19880262.001]
  • [Cites] Oncologist. 2002;7(4):342-7 [12185296.001]
  • [Cites] J Cancer Res Ther. 2006 Apr-Jun;2(2):79-81 [17998682.001]
  • [Cites] Gynecol Oncol. 1989 Jan;32(1):72-5 [2909450.001]
  • [Cites] Radiographics. 1999 Oct;19 Spec No:S103-16; quiz S264-5 [10517448.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S127-32 [17727936.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3113-9 [15284262.001]
  • (PMID = 19953258.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2848922
  •  go-up   go-down


6. Malzoni M, Spina V, Perniola G, Aleandri V, Mossa B, Iuele T, Imperato F: Laparoscopic surgery in treatment of stage IIb cervical cancer after neoadjuvant chemotherapy. A case report and review of the literature. Eur J Gynaecol Oncol; 2003;24(5):393-7
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic surgery in treatment of stage IIb cervical cancer after neoadjuvant chemotherapy. A case report and review of the literature.
  • BACKGROUND: A detailed operative procedure of laparoscopic radical hysterectomy (type III) with pelvic and aortic lymphadenectomy after neoadjuvant chemoterapy in treatment of Stage IIb cervical cancer is described.
  • CASE REPORT: A 50-year-old patient with Stage IIb squamous cell carcinoma of the uterine cervix, who initially was not surgically resectable, received three courses of neoadjuvant chemotherapy that included ifosfamide 5 g/m2, cisplatin 50 mg/m2 and paclitaxel 175 mg/m2 (TIP).
  • Following a partial clinical response to chemotherapy, the patient underwent laparoscopic type III radical hysterectomy with bilateral salpingo-oophorectomy and pelvic and paraaortic lymphadenectomy.
  • The surgical procedure lasted 250 minutes.
  • The patient also underwent adjuvant radiation therapy.
  • CONCLUSIONS: This experience suggests that such a surgical procedure is safe.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / surgery. Laparoscopy. Neoadjuvant Therapy. Uterine Cervical Neoplasms / surgery

  • Genetic Alliance. consumer health - Cervical cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14584654.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 24
  •  go-up   go-down


7. Chen CH, Chao KC, Wang PH: Advanced cervical squamous cell carcinoma with skin metastasis. Taiwan J Obstet Gynecol; 2007 Sep;46(3):264-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced cervical squamous cell carcinoma with skin metastasis.
  • OBJECTIVE: Although cervical cancer is a very common gynecologic malignancy, skin metastasis presenting as an initial sign of recurrent or persistent disease is extremely rare.
  • CASE REPORT: A 72-year-old woman was diagnosed with squamous cell carcinoma of the cervix (FIGO stage, IIB), which was treated with concurrent chemoradiation.
  • After treatment, she was followed up regularly, without evidence of disease.
  • Excision biopsy was performed and showed metastatic carcinoma, favoring a squamous cell type.
  • The patient then underwent a series of imaging examinations, including magnetic resonance imaging of the pelvis and computed tomography of the chest, and a whole body bone scan showed disseminated diseases involving the lung and bone.
  • Palliative chemotherapy was prescribed, and the skin lesions responded relatively well, but disease involving the vital organs still progressed during treatment.
  • CONCLUSION: This report supports the concept that skin metastasis is a late manifestation and an ominous sign for cervical cancer patients, and also indicates the uncontrolled or widespread metastasis of the disease.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Skin Neoplasms / secondary. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962107.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Tanaka H, Kondo E, Kawato H, Kikukawa T, Toyoda N: Aortitis during intraarterial chemotherapy for cervical cancer. Int J Clin Oncol; 2002 Feb;7(1):62-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aortitis during intraarterial chemotherapy for cervical cancer.
  • A 76-year-old woman with stage IIb cervical cancer with a bulky tumor experienced aortitis during continuous intraarterial cisplatin-based chemotherapy.
  • The chemotherapy was administered through a catheter tip placed in the aorta abdominalis, utilizing an external infusion pump.
  • During the third course of chemotherapy, she complained of left-sided lower back pain and moderate fever was observed.
  • Elevated white blood cell count (WBC) and C-reactive protein (CRP) level were noted, and an abdominal X-ray and urgent computed tomography (CT) were performed.
  • At this level of the aortic wall, soft tissue density surrounded the aorta completely.
  • Aortitis caused by the intraarterial chemotherapy, was strongly suspected.
  • It was thought that the maldistribution of drugs and changes in the drug flow occurred due to the vertebral height movement of the catheter tip against the aortic blood flow, and there, flow to the vasa vasorum may have occurred.
  • Chemical vasculitis of the vasa vasorum due to the anticancer drugs was strongly suspected as a contributing factor of the aortitis.
  • Because of the long-term use of an intraarterial catheter, the maldistribution of drugs and changes in the drug flow occurred physically and biologically during the course of the chemotherapy.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Aortitis / diagnosis. Carcinoma, Squamous Cell / drug therapy. Catheterization / adverse effects. Cisplatin / administration & dosage. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Infusions, Intra-Arterial / adverse effects. Magnetic Resonance Imaging. Neoplasm Staging. Tomography, X-Ray Computed


9. Lataifeh I, Amarin Z, Jaradat I: Stage IIB carcinoma of the cervix that is associated with pelvic kidney: A therapeutic dilemma. Am J Obstet Gynecol; 2007 Dec;197(6):e8-10
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IIB carcinoma of the cervix that is associated with pelvic kidney: A therapeutic dilemma.
  • Locally advanced cervical cancer with congenital pelvic kidney is reported uncommonly.
  • A 50-year-old patient with stage IIB cervical cancer and pelvic kidney was treated with irradiation and concurrent chemotherapy.
  • [MeSH-major] Kidney / abnormalities. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Female. Humans. Middle Aged. Radiotherapy. Urogenital Abnormalities / complications

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18060936.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Chen YL, He GQ, Wang ED: [Effect of preoperative chemotherapy on bulky cervical cancer by internal iliac arterial infusion]. Zhonghua Fu Chan Ke Za Zhi; 2005 Apr;40(4):231-4
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of preoperative chemotherapy on bulky cervical cancer by internal iliac arterial infusion].
  • OBJECTIVE: To evaluate the effect of preoperative chemotherapy on bulky cervical cancer by internal iliac arterial infusion.
  • METHODS: One hundred and eighty-six patients with bulky cervical cancer were randomly divided into two groups: chemotherapy + radiotherapy group (C + R group, n = 105) and radiotherapy group (R group, n = 81).
  • Patients in C + R group underwent internal iliac arterial infusion chemotherapy by using Seldinger technique internal iliac arterial or epigastric arterial catheterization.
  • Combined regimens were prescribed including cisplatin as the major drug.
  • Meanwhile 192Ir high-dose-rate intracavitary radiotherapy was performed, with A point dose at 12 - 24 Gy/2-4 times (C + R group).
  • The effective rate for clinical Ib stage cancer in C + R group was 100.0%, significantly higher than 78.3% in R group (P < 0.01), but for clinical IIa, IIb stage cancers, the effective rate between two groups had no obvious difference (P > 0.05).
  • Postoperative pathologic examinations showed the percentage of cervical tumor residue, parauterine invasion, pelvic lymph node metastasis in C + R group was lower than those of R group (P < 0.01).
  • CONCLUSIONS: Internal iliac arterial infusion chemotherapy can effectively reduce tumor volume, decrease lymph node and subclinical metastasis rates and postoperative recurrence rate; it can also improve radical resectability of patients with stage IIb cervical cancer.
  • [MeSH-major] Preoperative Period. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Infusions, Intra-Arterial. Middle Aged. Treatment Outcome. Tumor Burden / drug effects. Tumor Burden / radiation effects. Young Adult


11. Nagai T, Okubo T, Sakaguchi R, Seki H, Takeda S: Glassy cell carcinoma of the uterine cervix responsive to neoadjuvant intraarterial chemotherapy. Int J Clin Oncol; 2008 Dec;13(6):541-4
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glassy cell carcinoma of the uterine cervix responsive to neoadjuvant intraarterial chemotherapy.
  • Described as a poorly differentiated adenosquamous cancer, glassy cell carcinoma of the uterine cervix is a rare disease considered to have an extremely poor prognosis.
  • Saitama Medical Center has been offering neoadjuvant intraarterial chemotherapy (NAC) to cervical cancer patients as a means of avoiding postoperative radiation therapy, achieving downstaging, and improving prognosis.
  • We report a patient with glassy cell carcinoma of the uterine cervix who responded to NAC, and we discuss this case with reference to reports in the literature.
  • A 28-year-old gravida 1, para 0 patient was referred to the Department of Obstetrics and Gynecology at Saitama Medical Center for concurrent cervical cancer at 23.5 gestational weeks.
  • The patient was admitted to our center following the diagnosis of stage IIb cervical cancer (glassy cell carcinoma), to await fetal development, and an elective cesarean section was performed at slightly more than 29 gestational weeks.
  • It has been 6 years, to date, since the initial treatment, and our patient is alive and disease/recurrence free.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Combined Modality Therapy. Epirubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Hysterectomy. Infusions, Intra-Arterial. Neoadjuvant Therapy. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2003 May-Jun;13(3):308-12 [12801261.001]
  • [Cites] Gynecol Oncol. 1992 Mar;44(3):254-9 [1541437.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):61-9 [9345358.001]
  • [Cites] Am J Clin Pathol. 1991 Oct;96(4):520-8 [1716415.001]
  • [Cites] Gynecol Oncol. 1979 Oct;8(2):141-51 [499922.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2005 Aug;19(4):611-30 [15886059.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Mar;49(3):256-60 [11935219.001]
  • [Cites] Cancer. 1976 May;37(5):2238-46 [1260713.001]
  • [Cites] Lancet. 2000 Apr 1;355(9210):1159-60 [10791384.001]
  • [Cites] Cancer. 1956 Sep-Oct;9(5):971-9 [13364884.001]
  • [Cites] Semin Oncol. 2000 Feb;27(1 Suppl 1):23-7 [10697040.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 1995 Nov;35(4):408-12 [8717566.001]
  • (PMID = 19093183.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


12. Devkota B, Patel H: Meningeal carcinomatosis from cervical cancer: a case report and review of the literature. Hosp Pract (1995); 2010;38(3):117-21
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal carcinomatosis from cervical cancer: a case report and review of the literature.
  • Meningeal carcinomatosis (MC) from cervical cancer is rare.
  • We report an interesting case of MC from the uterine cervix and review general diagnostic and treatment considerations.
  • The patient received chemotherapy and radiotherapy for stage IIB cervical cancer with resolution of symptoms for 3 years.
  • Metastatic lesions were found in the right lung and paraaotic nodes on follow-up positron emission tomography scan, which completely resolved with subsequent chemotherapy.
  • Unfortunately, the patient developed neurological symptoms consistent with MC, which was confirmed by cerebrospinal fluid cytology.
  • [MeSH-major] Meningeal Carcinomatosis / secondary. Neoplasms, Squamous Cell / secondary. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20890060.001).
  • [ISSN] 2154-8331
  • [Journal-full-title] Hospital practice (1995)
  • [ISO-abbreviation] Hosp Pract (1995)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; cervical cancer / intrathecal / leptomeninges / meningeal carcinomatosis
  •  go-up   go-down


13. Huang YW, Li MD, Liu FY, Li YF: [Analysis of clinical efficiency of treatment for 179 geriatric women with stage I or II cervical carcinoma]. Ai Zheng; 2002 Nov;21(11):1238-40
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of clinical efficiency of treatment for 179 geriatric women with stage I or II cervical carcinoma].
  • BACKGROUND & OBJECTIVE: Elderly women with cervical carcinoma have the features of poor prognosis and high incidence rate of complications.
  • This study was designed to evaluate the prognostic impact of surgery versus radiotherapy in old women with stage I and stage II cervical carcinoma and seek suitable treatment for such patients.
  • METHODS: Clinical data of 179 elderly women with stage Ia to stage IIb cervical cancer were analyzed retrospectively.
  • One hundred and thirty-four cases underwent radical hysterectomy also received appropriate adjuvant radiotherapy and/or chemotherapy.
  • Forty-five cases underwent radiation therapy received appropriate adjuvant chemotherapy.
  • CONCLUSION: Geriatric patients with stage I and stage II cervical carcinoma should receive operation if possible and should receive adjuvant treatments according to personal conditions.
  • [MeSH-major] Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / surgery. Hysterectomy. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Brachytherapy. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Postoperative Complications. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12526224.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


14. Wu YY, Liang MR, Li LY, Zeng SY: [Analysis of 4223 hospitalized patients with cervical cancer during 1990-2007]. Zhonghua Fu Chan Ke Za Zhi; 2008 Jun;43(6):433-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 4223 hospitalized patients with cervical cancer during 1990-2007].
  • OBJECTIVE: To analyze the changes in epidemiology and treatment of hospitalized patients with cervical cancer during 1990-2007.
  • METHODS: Overall, 4648 patients with cervical cancer were diagnosed in our hospital from Jan 1990 to Nov 2007, but only 4223 patients with initial treatment in our hospital were studied retrospectively.
  • Pearson Chi-square test was used to compare the age, stage, histopathologic type and treatment methods between different times. RESULTS:.
  • (1) The mean age of cervical cancer patients gradually decreased over the past 18 years, from 54.4 years during 1990-1999 to 47.2 years during 2000-2007; the proportion of young patients aged < or = 35 years increased from 4.77% (89/1865) during 1990-1999 to 11.75% (277/2358) during 2000-2007. (2) The proportion of patients with cervical cancer (stage I a-II a) increased from 14.
  • 32% (267/1865) during 1990-1999 to 40.75% (961/2358) during 2000-2007, whereas the proportion of patients with cervical cancer (stage II b-IV) decreased from 85.68% (1598/1865) during 1990-1999 to 59.25% (1397/2358) during 2000-2007. (3) There was no significant change in histopathologic type of cervical cancer, and squamous cell carcinoma of cervix remained the main type of cervical cancer. (4) The treatment pattern of cervical cancer changed significantly: radiotherapy was the main method (75.28%) for cervical cancer during 1990-1999, but during 2000-2007, it was replaced by concurrent chemoradiotherapy (35.79%).
  • CONCLUSIONS: The proportion of young women with cervical cancer was increased during 1990-2007, and at the same period early stage cervical cancer increased, but late stage cervical cancer decreased.
  • It is obvious that chemotherapy has become the important therapy in cervical cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Carcinoma, Squamous Cell. Uterine Cervical Neoplasms
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Antineoplastic Protocols. Cervix Uteri / pathology. Combined Modality Therapy. Female. Humans. Incidence. Inpatients. Middle Aged. Neoplasm Staging. Radiotherapy. Retrospective Studies


15. Park TK, Kwon JY, Kim SW, Kim SH, Kim SN, Kim GE: Patterns of treatment failure following radiotherapy with combination chemotherapy for patients with high-risk stage IIB cervical carcinoma. Int J Clin Oncol; 2004 Apr;9(2):120-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of treatment failure following radiotherapy with combination chemotherapy for patients with high-risk stage IIB cervical carcinoma.
  • BACKGROUND: To evaluate the patterns of treatment failure in patients with stage IIB cervical carcinoma with high-risk factors following radiotherapy given concurrently with combination chemotherapy.
  • METHODS: A retrospective analysis of 349 patients with stage IIB cervical carcinoma with high-risk factors (lesion size >/= 4 cm, lymph node metastasis, high-risk cell type) treated by radiotherapy and cisplatin-based chemotherapy was performed.
  • Sites of treatment failure were categorized as pelvic, pelvic plus distant metastases, and distant metastases alone.
  • RESULTS: Of the 349 patients, treatment failure occurred in 79 patients (22.6%).
  • The incidences of pelvic failure alone and distant metastases were similar in the high-risk cell-type group, and the distant metastasis regions were mostly paraaortic lymph nodes.
  • CONCLUSION: Although systemic chemotherapy was administered concurrently with radiotherapy, the incidence of pelvic failure was highest, followed by paraaortic lymph node metastases, in patients with stage IIB cervical carcinoma with high-risk factors, following radiotherapy with combination chemotherapy.
  • To evaluate the patterns of treatment failure in patients with stage IIB cervical carcinoma with high-risk factors following radiotherapy given concurrently with combination chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / therapy. Radiotherapy / methods. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Brachytherapy. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Treatment Failure

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15108044.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Chen CA, Hsieh CY: Recent advances and problems in primary therapy for cervical cancer in Taiwan. J Formos Med Assoc; 2004 Jul;103(7):511-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances and problems in primary therapy for cervical cancer in Taiwan.
  • Cervical cancer is a serious health problem in Taiwan, with nearly 2700 women developing the disease each year.
  • Surgery and radiotherapy are the standard treatments for early stage cervical cancer.
  • For women with advanced stage cervical cancer, external-beam pelvic radiation followed by intracavitary radiotherapy is the treatment of choice.
  • Although randomized clinical trials have shown that concurrent chemoradiotherapy should be regarded as the standard treatment for locally advanced cervical cancer (stage IIB to IVA), the impact of the complications associated with this treatment have not been evaluated in Taiwanese studies.
  • Localized bulky (stage IB2 or bulky IIA) tumors are commonly treated with various combinations of chemotherapy, surgery and radiotherapy, despite unresolved concerns about the morbidity and effectiveness of this approach compared with definitive radiotherapy or radical surgery.
  • Although about 60% of Taiwanese women with cervical cancer receive primary surgical treatment, about 20% do not receive treatment or receive non-standard therapies.
  • Efforts are needed to increase the screening rate, to improve access to medical care, and to provide public education for patients to reduce the occurrence and mortality of cervical cancer in Taiwan.


17. Berclaz G, Gerber E, Beer K, Aebi S, Greiner R, Dreher E, Buser K: Long-term follow-up of concurrent radiotherapy and chemotherapy for locally advanced cervical cancer: 12-Year survival after radiochemotherapy. Int J Oncol; 2002 Jun;20(6):1313-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of concurrent radiotherapy and chemotherapy for locally advanced cervical cancer: 12-Year survival after radiochemotherapy.
  • Recently randomized trials show an overall survival advantage of 30% for cisplatin-based chemotherapy given concurrently with radiation therapy.
  • Current data do not allow to conclude which drugs could be best combined with cisplatin.
  • Here we report the very long-term results of a prospective phase II trial of concurrent radiochemotherapy in advanced cancer of the cervix.
  • Patient with squamous cell carcinoma of the cervix FIGO stage IIB, III or IVA received a concomitant chemotherapy with cisplatin, fluorouracil and mitomycin C and radiotherapy.
  • All 22 patients treated showed acute hematological toxicity and two patients developed severe late bowel toxicity.
  • Ten patients (45%) were alive after a median observation time of 145.5 months.
  • The lack of improvement compared to cisplatin alone and late bowel toxicity do not support the use of mitomycin C in the combination of the concurrent treatment of chemoradiation.
  • The psychological impact of this treatment should not be minimized.
  • Most problems tend to diminish with time with the exception of intestinal side effects and vaginal changes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Mitomycin / administration & dosage. Patient Compliance. Radiotherapy / adverse effects. Radiotherapy Dosage. Treatment Failure

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12012015.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


18. Yamashita H, Okuma K, Kawana K, Nakagawa S, Oda K, Yano T, Kobayashi S, Wakui R, Ohtomo K, Nakagawa K: Comparison between conventional surgery plus postoperative adjuvant radiotherapy and concurrent chemoradiation for FIGO stage IIB cervical carcinoma: a retrospective study. Am J Clin Oncol; 2010 Dec;33(6):583-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between conventional surgery plus postoperative adjuvant radiotherapy and concurrent chemoradiation for FIGO stage IIB cervical carcinoma: a retrospective study.
  • OBJECTIVE: To compare treatment outcome of conventional surgery followed by adjuvant postoperative radiotherapy (PORT) versus concurrent chemoradiation therapy (cCRT) for stage IIB cervical carcinoma.
  • METHODS: A retrospective analysis was conducted of 59 patients with stage IIB uterine cervical cancer treated with radical surgery plus PORT (N = 34) or cCRT-alone (N = 25) from April 1996 to June 2008.
  • The median follow-up time was 27 months (range, 3-150 months) in the cCRT group and 44 months (range, 4-134 months) in the PORT group.
  • The difference between these 2 treatments was not statistically significant (log-rank P = 0.5871).
  • CONCLUSION: This retrospective study suggests that survival results with cCRT and with conventional surgery plus PORT for patients with stage IIB cervical carcinoma are comparable.
  • [MeSH-major] Hysterectomy / methods. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chemotherapy, Adjuvant. Chi-Square Distribution. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Risk Assessment. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065848.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Cho NH, Kim YB, Park TK, Kim GE, Park K, Song KJ: P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. Gynecol Oncol; 2003 Nov;91(2):346-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma.
  • OBJECTIVES: The purpose of this study was to determine the relation between p63, p53-related gene, epidermal growth factor receptor (EGFR), and spontaneous apoptosis in relation to radiotherapy in patients with FIGO stage IIB cervical carcinoma, who had undergone radiation and concurrent chemotherapy, retrospectively.
  • METHODS: Eighty-four patients with FIGO stage IIB squamous cell carcinoma (SCC) of the uterine cervix, who were treated with radiotherapy and concurrent chemotherapy between 1991 and 1996, were included in the present study.
  • The clinicopathologic features, patterns of treatment failure, and survival data were compared with the expressions of p63 and EGFR, which were determined by immunohistochemistry and with apoptosis by TUNEL on tissue-arrayed slides.
  • RESULTS: Overall the indices of the expressions of p63 and EGFR in stage IIB cervical carcinoma were 18.7 and 26.6%, respectively, and these were found to be correlated.
  • Both molecules were found to be potent molecular risk factors in patients with FIGO stage IIB SCC of the uterine cervix, who had received radiotherapy and concurrent chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / radiotherapy. Membrane Proteins. Phosphoproteins / biosynthesis. Receptor, Epidermal Growth Factor / biosynthesis. Trans-Activators / biosynthesis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Apoptosis / physiology. Apoptosis / radiation effects. Combined Modality Therapy. DNA-Binding Proteins. Female. Gene Expression. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Transcription Factors. Tumor Suppressor Proteins


20. Gupta T, Nair N, Fuke P, Bedre G, Basu S, Shrivastava SK: Splenic metastases from cervical carcinoma: a case report. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):911-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic metastases from cervical carcinoma: a case report.
  • Splenic metastasis from squamous cell carcinoma of the uterine cervix is an unusual event in the natural history of the disease.
  • The authors report one such uncommon occurrence in a 41-year-old female who presented initially with cervical carcinoma (stage IIB) and was treated with radical radiotherapy with concurrent weekly chemotherapy.
  • Following a disease-free interval of less than a year, she developed hepatosplenic metastases despite being locally controlled.
  • This report reaffirms the notion that splenic metastases from cervical carcinoma are rare events but can occur as part of widespread dissemination.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Splenic Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Positron-Emission Tomography. Premenopause

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681784.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Marnitz S, Köhler C, Füller J, Hinkelbein W, Schneider A: Uterus necrosis after radiochemotherapy in two patients with advanced cervical cancer. Strahlenther Onkol; 2006 Jan;182(1):45-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterus necrosis after radiochemotherapy in two patients with advanced cervical cancer.
  • BACKGROUND: Simultaneous platinum-based radiochemotherapy is the standard of care for patients with advanced or node-positive cancer of the uterine cervix.
  • A large body of literature concerning therapy-related acute and late morbidity is available.
  • CASE REPORT: Two patients are reported who were treated by combined chemoradiation between 2004 and 2005 for histologically confirmed cervical cancer following laparoscopic staging.
  • Both patients were diagnosed with squamous cell cancer of the cervix FIGO stage IIB (T2b pN1 pM1 LYM G2) and FIGO IIIA (T3a pN1 M0 G2), respectively.
  • Patient #2 underwent 5 x 5 Gy brachytherapy covering the tumor.
  • Following chemoradiation, both patients developed pelvic pain and an elevation of C-reactive protein (CRP) in the presence of a normal leukocyte count.
  • CONCLUSION: In patients with persisting or incident pelvic pain, questionable findings in imaging techniques and/or elevated inflammation parameters following completion of chemoradiation for cervical cancer, differential diagnosis should include radiogenic necrosis of the uterus and other pelvic organs.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Radiation Injuries / etiology. Radiotherapy / adverse effects. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy. Uterus / pathology. Uterus / radiation effects
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Brachytherapy. Cervix Uteri / pathology. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Hysterectomy. Iridium Radioisotopes / therapeutic use. Laparoscopy. Middle Aged. Necrosis. Neoplasm Staging. Ovariectomy. Radiotherapy Dosage. Radiotherapy, Conformal. Time Factors


22. Kim YB, Kim GE, Pyo HR, Cho NH, Keum KC, Lee CG, Seong J, Suh CO, Park TK: Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys; 2004 Nov 1;60(3):822-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix.
  • PURPOSE: To determine the differential expression of cyclooxygenase-2 (COX-2) in patients with squamous cell carcinoma (SCC) and adenocarcinoma (ADC) of the uterine cervix and the prognostic significance of COX-2 expression in these histologic types.
  • METHODS AND MATERIALS: A total of 105 International Federation of Gynecology and Obstetrics Stage IIB uterine cervical cancer patients were screened for COX-2 expression immunohistochemically.
  • COX-2 expression was determined in invasive cervical SCC (n = 84) and invasive cervical ADC (n = 21).
  • To determine the clinical significance of COX-2 expression by histologic type, the patients were arbitrarily divided into four groups: SCC/COX-2 negative (n = 64); SCC/COX-2 positive (n = 20); ADC/COX-2 negative (n = 9); and ADC/COX-2 positive (n = 12).
  • The clinical response to treatment, patterns of treatment failure, and survival data by COX-2 expression were compared for these two major histologic types.
  • Moreover, COX-2 expression was an important predictor of treatment response, irrespective of the histologic type.
  • All COX-2-negative patients achieved complete remission after initial treatment; 17% of SCC patients and 33% of ADC patients with COX-2 expression did not have complete remission after the initial treatment.
  • The incidence of local failure for those with COX-2 expression was significantly greater than for COX-2-negative patients, regardless of histologic type.
  • Irrespective of the pathologic type, COX-2-positive patients had an unfavorable prognosis.
  • When patients were stratified into the four groups according to histologic type and COX-2 expression status, ADC/COX-2-positive patients had the worst prognosis, with an overall 5-year actuarial survival rate of 49% compared with 78% for ADC/COX-2-negative patients, 62% for SCC/COX-2-positive, and 84% for SCC/COX-2-negative patients (p = 0.007, log-rank test).
  • Irrespective of histologic type, COX-2 expression was an independent prognostic factor by univariate and multivariate analyses.
  • CONCLUSION: In uterine cervical cancer, COX-2 was expressed in a greater proportion of ADC patients than SCC patients.
  • COX-2 expression was also identified as a major determiner of a poor response to treatment and of an unfavorable prognosis, irrespective of the histologic type, reflecting the importance of the COX-2 protein in the acquisition of biologic aggressiveness and more malignant phenotype or increased resistance to the standard chemotherapy and radiotherapy in both histologic types.
  • Given these observations, we believe that that ADC/COX-2-positive patients might be appropriate candidates for future trials of selective COX-2 inhibitor adjunctive therapy.
  • [MeSH-major] Adenocarcinoma / enzymology. Carcinoma, Squamous Cell / enzymology. Isoenzymes / analysis. Neoplasm Proteins / analysis. Prostaglandin-Endoperoxide Synthases / analysis. Uterine Cervical Neoplasms / enzymology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15465199.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / Membrane Proteins; 0 / Neoplasm Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


23. Boyd A, Cowie V, Gourley C: The use of cisplatin to treat advanced-stage cervical cancer during pregnancy allows fetal development and prevents cancer progression: report of a case and review of the literature. Int J Gynecol Cancer; 2009 Feb;19(2):273-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of cisplatin to treat advanced-stage cervical cancer during pregnancy allows fetal development and prevents cancer progression: report of a case and review of the literature.
  • BACKGROUND: Cervical cancer is one of the most frequently encountered malignancies in pregnancy.
  • For early-stage disease arising in late second/third trimester, treatment may be delayed until delivery.
  • CASE: A 26-year-old woman presented at 21 weeks gestation with a stage IIB high-grade clear cell cervical carcinoma.
  • Fifteen months post treatment, both patient and baby remain well.
  • CONCLUSION: Neoadjuvant cisplatin chemotherapy can be used in stage IIB cervical carcinoma during pregnancy to allow fetal development and prevent disease progression before delivery.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Disease Progression. Female. Fetal Development / drug effects. Humans. Pregnancy


24. Mayer A, Nemeskéri C, Petneházi C, Borgulya G, Varga S, Naszály A: Primary radiotherapy of stage IIA/B-IIIB cervical carcinoma. A comparison of continuous versus sequential regimens. Strahlenther Onkol; 2004 Apr;180(4):209-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary radiotherapy of stage IIA/B-IIIB cervical carcinoma. A comparison of continuous versus sequential regimens.
  • BACKGROUND: Comprehensive literature on cervical cancer demonstrates, even today, the need for optimization of the timing of external-beam radiotherapy (EBRT) and high-dose-rate brachytherapy (HDR-BT) in the treatment of stage IIA/B-IIIB cervical carcinoma.
  • PATIENTS AND METHODS: 210 patients with carcinoma of the cervix were treated in the Municipal Center of Oncoradiology between January 1991 and December 1996 (FIGO IIA: n = 10, FIGO IIB: n = 113, and FIGO IIIB: n = 87).
  • Two regimens were compared: sequential radiation therapy (SRT) with 4 x 8 Gy HDR-BT to point A followed by EBRT, and continuous radiation therapy (CRT) in which 5 x 6 Gy HDR-BT to point A, one session per week, was integrated into the EBRT.
  • A total dose of 68-70 Gy to point A and 52-54 Gy to point B was given in EBRT with SRT, five fractions per week were applied.
  • Overall treatment time (OTT) amounted to 56 days for SRT and 35 days for CRT.
  • Median follow-up time was 3.4 (2.5-4.2) years.
  • The dose of 8 Gy per fraction of HDR-BT in the SRT regimen was obviously too high.
  • To achieve a significant improvement in local control and disease-free survival (DFS) as well as overall survival (OS), the combination with modern chemotherapy regimens and regional deep hyperthermia may rather be the treatment option.
  • [MeSH-major] Brachytherapy. Carcinoma, Squamous Cell / radiotherapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Cervix Uteri / pathology. Confidence Intervals. Cystoscopy. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Neoplasm Staging. Proportional Hazards Models. Radiography, Abdominal. Radiotherapy Dosage. Regression Analysis. Survival Analysis. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Strahlenther Onkol. 2005 Jan;181(1):54 [15660194.001]
  • (PMID = 15057431.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


25. Nasu K, Takai N, Narahara H: Multimodal treatment for glassy cell carcinoma of the uterine cervix. J Obstet Gynaecol Res; 2009 Jun;35(3):584-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal treatment for glassy cell carcinoma of the uterine cervix.
  • Glassy cell carcinoma of the uterine cervix is a rare form of cervical cancer that is characterized by aggressiveness and poor prognosis because of its rapid growth, its frequent distant metastases, and its relative resistance to conventional treatment modalities including surgery, radiotherapy, and chemotherapy.
  • We report here a case of glassy cell carcinoma of the uterine cervix that was successfully treated with radical surgery followed by radiation therapy and combination chemotherapy with paclitaxel and carboplatin.
  • A 30-year-old primigravid Japanese woman was admitted to our hospital to be treated for stage IIb uterine cervical cancer.
  • The pathological diagnosis of the surgical specimen was glassy cell carcinoma of the uterine cervix with metastases to the right obturator lymph nodes and left external iliac lymph nodes.
  • Subsequently, she was treated using conventional radiation therapy (50Gy by whole pelvic radiation) and six courses of tri-weekly chemotherapy with paclitaxel (180 mg/m(2)) and carboplatin (area under the curve of 6.0 mg min/mL calculated using the Calvert formula).
  • It is suggested that multimodal therapy with radical surgery, radiation, and combined chemotherapy should be used to treat glassy cell carcinoma of the uterine cervix.
  • Our multimodal treatment protocol may be one of the treatment options for this aggressive disease.
  • [MeSH-major] Carcinoma, Adenosquamous / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Female. Humans. Hysterectomy. Lymph Node Excision. Paclitaxel / administration & dosage. Radiotherapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19527406.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


26. Palaia I, Angioli R, Cutillo G, Manci N, Panici PB: Skin relapse from cervical cancer. Gynecol Oncol; 2002 Oct;87(1):155-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin relapse from cervical cancer.
  • BACKGROUND: Cutaneous lymphangitis carcinomatosis from cervical carcinoma is a very rare form of tumor metastatization; only anecdotal cases are reported in the literature.
  • CASE: A case of cutaneous lymphangitis carcinomatosis mimicking contact dermatitis was diagnosed at our institution in a patient affected by cervical carcinoma stage IIB.
  • Palliative chemotherapy with paclitaxel was started and the patient experienced complete clinical response.
  • CONCLUSION: In a woman with a history of cervical cancer, a diffuse pruritic skin eruption should alert the clinician to the possibility of cutaneous carcinomatous lymphangitis.
  • If a lymphangitis carcinomatosis is diagnosed, systemic intravenous chemotherapy should be considered.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Skin Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Lymphangitis / pathology. Middle Aged. Paclitaxel / therapeutic use


27. Dubay RA, Rose PG, O'Malley DM, Shalodi AD, Ludin A, Selim MA: Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. Gynecol Oncol; 2004 Jul;94(1):121-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer.
  • OBJECTIVE: To analyze the toxicity profile and long-term outcomes of patients receiving carboplatin with concurrent radiation for locally advanced cervical cancer.
  • METHODS: A retrospective study was performed to identify patients treated with carboplatin and concurrent radiation therapy for locally advanced cervical cancer with a minimum follow-up period of 24 months.
  • Records were reviewed for demographic data, chemotherapy doses, toxicities, and survival outcomes.
  • Specifically reviewed were hematologic, gastrointestinal, and renal toxicities and the need for dose modification and treatment delays.
  • RESULTS: Twenty-one patients with cervical carcinoma Stage IIB (7), III (13), or IVA (1) treated with carboplatin chemotherapy from 1993 to 2001 were identified.
  • Carboplatin at a dose of 300 mg/m(2) administered every 3 weeks for an intended six courses was initiated at the start of radiation therapy.
  • Nine patients had delays in chemotherapy administration and/or received a 25% reduction in the dose of chemotherapy based on one or more of the following: thrombocytopenia (platelet count <100000 cells/mcl) (n = 3), granulocytopenia (ANC <1.0) (n = 4), or anemia (hemoglobin <10.0 g/dl) (n = 5).
  • Six patients developed recurrent disease (five local and one distant) with a pelvic control rate of 76% and an overall survival of 71%.
  • CONCLUSION: Carboplatin at a dose of 300 mg/m(2) (equivalent to an AUC of 3.9) on an every 3-week schedule is tolerable with concurrent pelvic radiation therapy for locally advanced cervical cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Drug Administration Schedule. Female. Humans. Middle Aged. Neoplasm Staging. Radiotherapy / adverse effects. Retrospective Studies. Treatment Outcome






Advertisement